Intellectual property
Protecting innovation to create a greater impact.
Our growing intellectual property portfolio is designed to protect our non-genetic, non-viral recognition engineering platform and enable long-term value for patients, partners, and shareholders.
A multi-dimensional IP architecture.
27 provisional patent applications across 13+ distinct inventive embodiments, organized into four PCT filing groups.
Provisional patent applications
Inventive embodiments
IP domains
PCT filing groups
Signal layer
NeoTag™
Design, selection, and installation of immune-recognizable signals: composition, density, and persistence.
Installation layer
Atraxis™
Membrane-interactive, non-genetic delivery: vesicle fusion, anchoring, and adaptive architectures.
System integration
StratIQ™
Coordinated multi-component designs, sequential and combinatorial deployment, and integration with existing modalities.
Control layer
AegisCore™
Contextual activation, temporal control, safety gating, and multi-factor authorization.
Illustration is conceptual.
Defensible by design.
Intentional overlap
Replicating the full platform would require navigating multiple independent patent domains at once, combined with trade secrets covering configuration and optimization.
A staged international filing strategy.
Each filing group is anchored to its earliest priority provisional and organized around a distinct inventive plane, designed to preserve priority dates and secure protection across every plane.
Atraxis™
Delivery mechanics: vesicle fusion and surface installation.
NeoTag™
Immune identity: signal design, selection, and presentation.
AegisCore™
Authorization logic: contextual activation and safety gating.
StratIQ™
Advanced architectures: system-level coordination.
Foundations in place
Priority established
June 24, 2025
Controlling priority date set by the first provisional filing.
Provisional portfolio
27 applications
Filed across 13+ distinct inventive embodiments.
Claims matrix v2
December 2025
Claims consolidated with counsel, adding fallback and defensive positions.
International filing package
May 2026
ePCT setup, declarations, and assignments finalized.
Next: national and regional phase entries, within 30 months of each priority date.
Filing status reflects the company’s staged 2026 plan. Patent applications are pending; no patents have been granted.
Patent prosecution
Drafting and prosecution of every filing, managed by Hayes Soloway P.C.
Claims strategy
A consolidated claims matrix with fallback and defensive catch-all positions.
Priority management
Each filing group anchored to its earliest priority provisional.
International filings
Four PCT filing groups staged across 2026, with U.S. non-provisional conversions.
Patent counsel of record
Prosecution led by specialist counsel.
Patent prosecution is managed by Hayes Soloway P.C., a nationally recognized biotechnology patent firm, with Nick Soloway, Esq. leading prosecution. Their oversight reinforces the rigor behind the platform.
Visit Hayes Soloway“IP protects design architecture and inventive concepts, independent of validation status.”
LurexBio intellectual property framework
Key areas of coverage
Coverage of the core components that make up the recognition engineering platform: the NeoTag™ signal, the Atraxis™ delivery architecture, and the AegisCore™ and StratIQ™ control layers.
How the platform is designed to be applied, including installation and recognition methods.
Approaches to producing and formulating platform components.
Use alongside existing and emerging immunotherapy modalities, including checkpoint inhibitors, T-cell engagers, and cell therapies.
Applications across immune-cold indications, beginning with MSS colorectal cancer and pancreatic cancer.
Questions about partnering or licensing? Contact us
Platform compositionProtecting the work.
Each platform component receives independent intellectual property protection, building a defensible estate around the delivery platform, the immune flag, and the methods that connect them.